ODI PHARMA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.7 SEK | 0.00% |
|
+4.59% | +14.00% |
| Feb. 22 | ODI Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 | CI |
| 2023 | ODI Pharma Sells CBD Skincare Brand for SEK3 Million | MT |
Valuation
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 85.23 | 67.88 | 82.19 | 83.71 |
| Enterprise Value (EV) 1 | 64.72 | 53.26 | 74.82 | 77.22 |
| P/E ratio | -15.6 x | -17.2 x | -11.3 x | -12.2 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 262,633,493 x | 600,256,710 x |
| EV / Revenue | - | - | 239,089,567 x | 553,698,961 x |
| EV / EBITDA | -13.1 x | -13.5 x | -10.4 x | -11.3 x |
| EV / FCF | -21,372,769 x | -11,580,653 x | -15,782,997 x | 51,460,325 x |
| FCF Yield | -0% | -0% | -0% | 0% |
| Price to Book | 4.25 x | 4.16 x | 8.87 x | 32.5 x |
| Nbr of stocks (in thousands) | 15,220 | 15,220 | 15,220 | 15,220 |
| Reference price 2 | 5.600 | 4.460 | 5.400 | 5.500 |
| Announcement Date | 11/19/20 | 11/18/21 | 11/25/22 | 11/24/23 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | - | - | - | 0.3129 | 0.1395 |
| EBITDA 1 | -3.339 | -4.922 | -3.957 | -7.201 | -6.807 |
| EBIT 1 | -3.341 | -4.934 | -3.964 | -7.207 | -6.811 |
| Operating Margin | - | - | - | -2,302.98% | -4,884.2% |
| Earnings before Tax (EBT) 1 | -3.35 | -4.942 | -3.967 | -7.236 | -6.895 |
| Net income 1 | -3.633 | -4.962 | -3.982 | -7.239 | -6.901 |
| Net margin | - | - | - | -2,313.25% | -4,948.58% |
| EPS 2 | -0.2900 | -0.3600 | -0.2600 | -0.4800 | -0.4500 |
| Free Cash Flow | - | -3.028 | -4.599 | -4.741 | 1.501 |
| FCF margin | - | - | - | -1,514.86% | 1,075.97% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 11/19/20 | 11/19/20 | 11/18/21 | 11/25/22 | 11/24/23 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 4.42 | 20.5 | 14.6 | 7.37 | 6.49 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | -3.03 | -4.6 | -4.74 | 1.5 |
| ROE (net income / shareholders' equity) | - | -41.1% | -21.9% | -56.6% | -117% |
| ROA (Net income/ Total Assets) | - | -24.3% | -13.1% | -32.9% | -45.6% |
| Assets 1 | - | 20.38 | 30.33 | 22 | 15.14 |
| Book Value Per Share 2 | 0.3200 | 1.320 | 1.070 | 0.6100 | 0.1700 |
| Cash Flow per Share 2 | 0.3500 | 1.350 | 0.9600 | 0.4800 | 0.4300 |
| Capex 1 | 0.01 | 0.02 | - | 0 | - |
| Capex / Sales | - | - | - | 1.31% | - |
| Announcement Date | 11/19/20 | 11/19/20 | 11/18/21 | 11/25/22 | 11/24/23 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +14.00% | 7.91M | |
| +25.83% | 661B | |
| +26.14% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.51% | 231B | |
| +5.24% | 200B | |
| -9.04% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ODI Stock
- Financials ODI Pharma AB
